Ad26.Mos4.HIV

AXP000174.1 · Vaccine

Platform
human adenovirus 26 (non-replicating)
Targets
HIV-1 Env; HIV-1 Gag; HIV-1 Pol
Originator
Janssen Vaccines & Prevention
Sponsor
Johnson & Johnson

Names

NameTypeSource
Ad26.Mos4.HIVpreferred name, codecurator, press
Ad26.Mos4.HIV-1 ambiguouscodepress

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
human adenovirus 26
Strain
Ad26
Replication
non replicating
Modifications
non-replicating Ad26 encoding four mosaic HIV-1 antigens; given with an adjuvanted clade C plus mosaic gp140 protein boost
Transgenes
HIV-1 mosaic Env, HIV-1 mosaic Gag, HIV-1 mosaic Pol
Route
intramuscular
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (8)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06205056Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy AdultsRecruitingPhase 12024-01-302025-1278Human Immunodeficiency Virus
NCT05769569Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV RemissionWithdrawnPhase 12023-09-012025-07-010HIV-1-infection
NCT04983030Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected AdultsCompletedPhase 1/22022-04-012026-02-2328Acquired Immunodeficiency Syndrome; HIV; Immunologic Deficiency Syndrome, Acquired; Retroviridae Infections; Sexually Transmitted Diseases, Viral
NCT03964415A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender IndividualsCompletedPhase 32019-10-312023-08-103900Healthy
NCT03307915A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral TreatmentCompletedPhase 12018-03-052021-11-0525Human Immunodeficiency Virus
NCT03060629A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan AfricaTerminatedPhase 22017-11-032022-02-022636HIV-1
NCT02935686A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected AdultsCompletedPhase 1/22017-03-312023-11-22155Healthy
NCT02788045Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected AdultsCompletedPhase 1/22016-07-082022-04-25201Healthy

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42673762Quantifying how HIV-1 envelope sequence features impact vaccine efficacy in the HVTN 705/HPX2008 randomised trial in southern African women.EBioMedicine2026name in abstract: Ad26.Mos4.HIV
PMID 40190112A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials.Emerging microbes & infections2025cited by trial NCT03060629
PMID 41314741Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial.The lancet. HIV2025cited by trial NCT03964415
PMID 39038477Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.The Lancet. Infectious diseases2024cited by trial NCT03060629
PMID 39236556Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study.EBioMedicine2024name in abstract: Ad26.Mos4.HIV
PMID 36348617Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study.The Journal of infectious diseases2023cited by trial NCT02935686
PMID 33010242Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.The lancet. HIV2020cited by trial NCT02788045
PMID 30047376Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).Lancet (London, England)2018cited by trial NCT03060629

NIH grants

ProjectTitleOrganisationPIYearsLinked by
U19AI128751Project 2BETH ISRAEL DEACONESS MEDICAL CENTERSCHUITEMAKER, HANNEKE2018–2022name in abstract: Ad26.Mos4.HIV

Notes

Ad26 vector delivering four mosaic HIV-1 immunogens, given as four injections over a year with a clade C and mosaic gp140 protein boost in the last two doses. The phase 3 Mosaico trial (HVTN 706) was stopped in January 2023 for lack of efficacy. The related phase 2b Imbokodo regimen (HVTN 705) used Ad26.Mos.HIV, a different antigen set, which did not reach phase 3 and is not entered.

How to cite

Ad26.Mos4.HIV (AXP000174.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000174.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.